| Identification | Back Directory | [Name]
demethylzeylasteral | [CAS]
107316-88-1 | [Synonyms]
demethylzeylasteral
Demethylzeylasteral(T-96)
A-Friedo-24-noroleana-1,3,5(10),7-tetraen-29-oicacid
24,25,26-Trinoroleana-1,3,5(10),7-tetraen-29-oic acid, 2,3-dihydroxy-9,13-dimethyl-6,23-dioxo-, (9β,13α,14β,20α)-
(9beta,13alpha,14beta,20alpha)-2,3-Dihydroxy-9,13-dimethyl-6,23-dioxo-24,25,26-trinoroleana-1,3,5(10),7-tetraen-29-oic acid | [Molecular Formula]
C29H36O6 | [MDL Number]
MFCD16660658 | [MOL File]
107316-88-1.mol | [Molecular Weight]
480.59 |
| Chemical Properties | Back Directory | [Melting point ]
>221°C (dec.) | [Boiling point ]
663.6±55.0 °C(Predicted) | [density ]
1.31 | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
4.78±0.70(Predicted) | [color ]
Yellow |
| Hazard Information | Back Directory | [Uses]
Demethylzeylasteral is a natural product as new inhibitor to block the Bcl-XL-Bid interaction. Also, it is an immunosuppressive monomer isolated from the root xylem of Tripterygium wilfordii. It exhibits inhibition towards the glucuronidation elimination reaction of SN-38. | [Definition]
ChEBI: A carbopolycyclic compound with formula C29H36O6, originally isolated from Tripterygium wilfordii. | [in vivo]
Demethylzeylasteral (30 mg/kg, 6 times every 2 days, i.p.) inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis[1].
Demethylzeylasteral (4 mg/kg, 5 weeks, i.p.) inhibits the invasion of triple negative breast cancer by blocking classical and non classical TGF - β signaling pathways[2].
Demethylzeylasteral (30-120 mg/kg, 8 weeks, i.p.) improves inflammation in a unilateral ureteral obstruction rat model by inhibiting the activation of the NF - κ B pathway[4].
Demethylzeylasteral (10, 40 mg/kg, 30 days, i.g.) can alleviate atherosclerosis in AS rabbits[5].
Demethylzeylasteral (10, 20 mg/kg, 4 weeks, p.o.) improves CCl4 induced liver fibrosis in mice by inhibiting AGAP2 mediated FAK/AKT signaling[6]. | Animal Model: | Female nude mice modeled with glioma LN-229 cells[1]. | | Dosage: | 30 mg/kg, 6 times every 2 days | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Reduced tumor volume |
| Animal Model: | Female BALB/c mice modeled with 4T1 cells[2]. | | Dosage: | 4 mg/kg, 5 weeks | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Reduced cancer lung metastasis |
| Animal Model: | Rat model of unilateral ureteral obstruction[4]. | | Dosage: | 30-120 mg/kg, 8 weeks | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Inhibited the increases in serum creatinine, blood urea nitrogen and Up/Ucr ratio |
| Animal Model: | Atherosclerotic rabbit[5]. | | Dosage: | 10, 40 mg/kg, 30 days | | Administration: | Intragastrical (i.g.) | | Result: | Reduced blood lipids triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL-C) |
| Animal Model: | CCl4-induced liver fibrosis model[6]. | | Dosage: | 10, 20 mg/kg, 4 weeks | | Administration: | Oral gavage (p.o.) | | Result: | Inhibited the expression of TGF-β1 |
| [storage]
Store at 2-8°C,protect from light |
|
|